Welcome to GSK’s product website

Here you will find information about GSK’s medicines and vaccines

I’m a UK healthcare professional

Important notice: this site is intended for UK healthcare professionals. By entering this site, you are confirming that you are a UK healthcare professional. This site may contain promotional information.

I’m a member of the UK public

This site is intended for members of the UK public, patients and their carers.

M.C. Last updated: March 2018. UK/COM/0106/15(2)

M.C. Last updated: March 2018. UK/COM/0106/15(2)

menu_icon

Relvar Ellipta is indicated for the regular
treatment of patients with asthma ≥12 years
where use of a combination product (longacting
ß2-agonist and inhaled corticosteroid) is
appropriate:

  • Patients not adequately controlled with
    inhaled corticosteroids and ‘as-needed’
    inhaled short-acting ß2-agonists
  • Patients already adequately controlled
    on both inhaled corticosteroids and long
    acting ß2-agonists1

24 hours of continuous efficacy
in Asthma
from only one daily inhalation

Relvar is an ICS/LABA licensed in Asthma which
could help your patients with asthma stand up to a
24-hour world.1

Relvar Ellipta asthma control